Citations

Mayo Clinic

Showing 10 of 108522 citations.

Occipital nerve block for the short-term preventive treatment of migraine: A randomized, double-blinded, placebo-controlled study
Dilli, Esma, Halker, Rashmi, Vargas, Bert B., Hentz, Joseph G. , Radam, Teresa, Rogers, Robert , Vargas, Bert, Hentz, Joseph, Dodick, David, Dodick, David W.

Cephalalgia | December 12, 2014 | Volume: 35 | Issue: 11 | Pages: 959-968

10.1177/0333102414561872 | PMID 25505035 Get It

Background Occipital nerve (ON) injections with corticosteroids and/or local anesthetics have been employed for the acute and preventive treatment of migraine for decades. However, to date there is no randomized, placebo-controlled evidence to support the use of occipital nerve block (ONB) for the prevention of migraine. Objective The objective of this article is to determine the efficacy of ONB with local anesthetic and corticosteroid for the preventive treatment of migraine. Participants and methods Patients between 18 and 75 years old with ICHD-II-defined episodic (> 1 attack per week) or chronic migraine (modified ICHD-II as patients with > 10 days with consumption of acute medications were permitted into the study) were randomized to receive either 2.5 ml 0.5% bupivacaine plus 0.5 ml (20 mg) methylprednisolone over the ipsilateral (unilateral headache) or bilateral (bilateral headache) ON or 2.75 ml normal saline plus 0.25 ml 1% lidocaine without epinephrine (placebo). Patients completed a one-month headache diary prior to and after the double-blind injection. The primary outcome measure was defined as a 50% or greater reduction in the frequency of days with moderate or severe migraine headache in the four-week post-injection compared to the four-week pre-injection baseline period. Results Thirty-four patients received active and 35 patients received placebo treatment. Because of missing data, the full analysis of 33 patients in the active and 30 patients in the placebo group was analyzed for efficacy. In the active and placebo groups respectively, the mean frequency of at least moderate (mean 9.8 versus 9.5) and severe (3.6 versus 4.3) migraine days and acute medication days (7.9 versus 10.0) were not substantially different at baseline. The percentage of patients with at least a 50% reduction in the frequency of moderate or severe headache days was 30% for both groups (10/30 vs nine of 30, Δ 0.00, 95% CI –0.22 to 0.23). Conclusions Greater ONB does not reduce the frequency of moderate to severe migraine days in patients with episodic or chronic migraine compared to placebo. The study was registered with ClinicalTrial.gov (NCT00915473).
Late-life migraine accompaniments: A narrative review
Vongvaivanich, Kiratikorn , Lertakyamanee, Paweena, Silberstein, Stephen D., Dodick, David W.

Cephalalgia | December 12, 2014 | Volume: 35 | Issue: 10 | Pages: 894-911

10.1177/0333102414560635 | PMID 25505036 Get It

Background Migraine is one of the most common chronic neurological disorders. In 1980, C. Miller Fisher described late-life migraine accompaniments as transient neurological episodes in older individuals that mimic transient ischemic attacks. There has not been an update on the underlying nature and etiology of late-life migraine accompanimentsd since the original description. Purpose The purpose of this article is to provide a comprehensive and extensive review of the late-life migraine accompaniments including the epidemiology, clinical characteristics, differential diagnosis, and treatment. Methods Literature searches were performed in MEDLINE®, PubMed, Cochrane Library, and EMBASE databases for publications from 1941 to July 2014. The search terms “Migraine accompaniments,” “Late life migraine,” “Migraine with aura,” “Typical aura without headache,” “Migraine equivalents,” “Acephalic migraine,” “Elderly migraine,” and “Transient neurological episodes” were used. Conclusion Late-life onset of migraine with aura is not rare in clinical practice and can occur without headache, especially in elderly individuals. Visual symptoms are the most common presentation, followed respectively by sensory, aphasic, and motor symptoms. Gradual evolution, the march of transient neurological deficits over several minutes and serial progression from one symptom to another in succession are typical clinical features for late-life migraine accompaniments. Transient neurological disturbances in migraine aura can mimic other serious conditions and can be easily misdiagnosed. Careful clinical correlation and appropriate investigations are essential to exclude secondary causes. Treatments are limited and still inconsistent.
Use and Outcomes Associated With Bridging During Anticoagulation Interruptions in Patients With Atrial Fibrillation
Kim, Sunghee , Thomas, Laine , Fonarow, Gregg C. , Kowey, Peter R. , Mahaffey, Kenneth W. , Sherwood, Matthew W. , Chang, Paul, Piccini, Jonathan P. , Ansell, Jack , Steinberg, Benjamin A. , Peterson, Eric D. , Gersh, Bernard J.

Circulation | December 12, 2014 | Volume: 131 | Issue: 5 | Pages: 488-494

10.1161/circulationaha.114.011777 | PMID 25499873 Get It

Background— Temporary interruption of oral anticoagulation for procedures is often required, and some propose using bridging anticoagulation. However, the use and outcomes of bridging during oral anticoagulation interruptions in clinical practice are unknown. Methods and Results— The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry is a prospective, observational registry study of US outpatients with atrial fibrillation. We recorded incident temporary interruptions of oral anticoagulation for a procedure, including the use and type of bridging therapy. Outcomes included multivariable-adjusted rates of myocardial infarction, stroke or systemic embolism, major bleeding, cause-specific hospitalization, and death within 30 days. Of 7372 patients treated with oral anticoagulation, 2803 overall interruption events occurred in 2200 patients (30%) at a median follow-up of 2 years. Bridging anticoagulants were used in 24% (n=665), predominantly low-molecular-weight heparin (73%, n=487) and unfractionated heparin (15%, n=97). Bridged patients were more likely to have had prior cerebrovascular events (22% versus 15%; P =0.0003) and mechanical valve replacements (9.6% versus 2.4%; P <0.0001); however, there was no difference in CHA 2 DS 2 -VASc scores (scores ≥2 in 94% versus 95%; P =0.5). Bleeding events were more common in bridged than nonbridged patients (5.0% versus 1.3%; adjusted odds ratio, 3.84; P <0.0001). The incidence of myocardial infarction, stroke or systemic embolism, major bleeding, hospitalization, or death within 30 days was also significantly higher in patients receiving bridging (13% versus 6.3%; adjusted odds ratio, 1.94; P =0.0001). Conclusions— Bridging anticoagulation is used in one quarter of anticoagulation interruptions and is associated with higher risk for bleeding and adverse events. These data do not support the use of routine bridging, and additional data are needed to identify best practices concerning anticoagulation interruptions. Clinical Trial Registration— URL: http://www.clinicaltrials.gov . Unique identifier: NCT01165710.
Vascular contributions to cognitive impairment and dementia including Alzheimer's disease
Snyder, Heather M. , Corriveau, Roderick A. , Craft, Suzanne , Faber, James E. , Greenberg, Steven M. , Lamb, Bruce T. , Montine, Thomas J. , Schaffer, Chris B. , Wellington, Cheryl L. , Zipfel, Gregory J. , Bain, Lisa J. , Bosetti, Francesca , Galis, Zorina S. , Carrillo, María C. , Knopman, David S. , Nedergaard, Maiken , Schneider, Julie A. , Wilcock, Donna M. , Zloković, Berislav V. , Koroshetz, Walter J. , Galis, Zorina S

Alzheimer's & Dementia | December 12, 2014 | Volume: 11 | Issue: 6 | Pages: 710-717

10.1016/j.jalz.2014.10.008 | PMID 25510382 Get It

Abstract Scientific evidence continues to demonstrate the linkage of vascular contributions to cognitive impairment and dementia such as Alzheimer's disease. In December, 2013, the Alzheimer's Association, with scientific input from the National Institute of Neurological Disorders and Stroke and the National Heart, Lung and Blood Institute from the National Institutes of Health, convened scientific experts to discuss the research gaps in our understanding of how vascular factors contribute to Alzheimer's disease and related dementia. This manuscript summarizes the meeting and the resultant discussion, including an outline of next steps needed to move this area of research forward.
Activation of the transforming growth factor‐β/SMAD transcriptional pathway underlies a novel tumor‐promoting role of sulfatase 1 in hepatocellular carcinoma
Dhanasekaran, Renumathy , Nakamura, Ikuo , Hu, Chunling , Oseini, Abdul M., Seven, Elif S. , Miamen, Alexander G., Moser, Catherine D., Zhou, Wei , Kuppevelt, Toin H. Van , Deursen, Jan M. van , Mounajjed, Taofic, Fernández-Zapico, Martín E. , Roberts, Lewis R. , Chen, Gang , Roberts, Lewis R , Dhanasekaran, Renumathy , Hu, Chunling

Hepatology | December 12, 2014 | Volume: 61 | Issue: 4 | Pages: 1269-1283

10.1002/hep.27658 | PMID 25503294 Get It

In vitro studies have proposed a tumor suppressor role for sulfatase 1 (SULF1) in hepatocellular carcinoma (HCC); however, high expression in human HCC has been associated with poor prognosis. The reason underlying this paradoxical observation remains to be explored. Using a transgenic (Tg) mouse model overexpressing Sulf1 (Sulf1‐Tg), we assessed the effects of SULF1 on the diethylnitrosamine model of liver carcinogenesis. Sulf1‐Tg mice show a higher incidence of large and multifocal tumors with diethylnitrosamine injection compared to wild‐type mice. Lung metastases were found in 75% of Sulf1‐Tg mice but not in wild‐type mice. Immunohistochemistry, immunoblotting, and reporter assays all show a significant activation of the transforming growth factor‐β (TGF‐β)/SMAD transcriptional pathway by SULF1 both in vitro and in vivo . This effect of SULF1 on the TGF‐β/SMAD pathway is functional; overexpression of SULF1 promotes TGF‐β‐induced gene expression and epithelial–mesenchymal transition and enhances cell migration/invasiveness. Mechanistic analyses demonstrate that inactivating mutation of the catalytic site of SULF1 impairs the above actions of SULF1 and diminishes the release of TGF‐β from the cell surface. We also show that SULF1 expression decreases the interaction between TGF‐β1 and its heparan sulfate proteoglycan sequestration receptor, TGFβR3. Finally, using gene expression from human HCCs, we show that patients with high SULF1 expression have poorer recurrence‐free survival (hazard ratio 4.1, 95% confidence interval 1.9‐8.3; P = 0.002) compared to patients with low SULF1. We also found strong correlations of SULF1 expression with TGF‐β expression and with several TGF‐β‐related epithelial–mesenchymal transition genes in human HCC. Conclusion : Our study proposes a novel role of SULF1 in HCC tumor progression through augmentation of the TGF‐β pathway, thus defining SULF1 as a potential biomarker for tumor progression and a novel target for drug development for HCC. (H epatology 2015;61:1269–1283)
Protein Kinase Inhibitor Therapy in Advanced Thyroid Cancer: Ethical Challenges and Potential Solutions
Bible, Keith C. , Rosenthal, M. Sara, Ain, Kenneth B.

International Journal of Endocrine Oncology | December 12, 2014 | Volume: 1 | Issue: 2 | Pages: 145-151

10.2217/ije.14.24 Get It

Creating Master Endocrine Surgeons
Farley, David R.

International Journal of Endocrine Oncology | December 12, 2014 | Volume: 1 | Issue: 2 | Pages: 125-131

10.2217/ije.14.21 Get It

Modern Advances in Cardiovascular Imaging: Cardiac Computed Tomography and Cardiovascular Mri in Pericardial Disease
McRee, Chad, Mergo, Patricia J. , Parikh, Pragnesh , Pollak, Amy W., Shapiro, Brian P. , McRee, Chad W

Future Cardiology | December 12, 2014 | Volume: 10 | Issue: 6 | Pages: 769-779

10.2217/fca.14.61 | PMID 25495818 Get It

Atrial Fibrillation in the Elderly: A Review
Hakim, Fayaz A., Shen, Win-Kuang

Future Cardiology | December 12, 2014 | Volume: 10 | Issue: 6 | Pages: 745-758

10.2217/fca.14.32 | PMID 25495816 Get It

Predictors of excellent functional outcome in aneurysmal subarachnoid hemorrhage
Pegoli, Marianna, Mandrekar, Jay , Rabinstein, Alejandro A. , Lanzino, Giuseppe

Journal of Neurosurgery | December 12, 2014 | Volume: 122 | Issue: 2 | Pages: 414-418

10.3171/2014.10.jns14290 | PMID 25495745 Get It

OBJECT Case fatality rates after aneurysmal subarachnoid hemorrhage (aSAH) have decreased over time, and many patients treated with modern paradigms return to a normal life. However, there is little information on predictors of excellent functional outcome after aSAH. In this study, the authors investigated predictors of excellent outcome in a modern consecutive series of patients with aSAH. METHODS A retrospective review was conducted of patients with aSAH admitted between 2001 and 2013. The primary outcome measure was excellent functional outcome, defined as modified Rankin Scale (mRS) score of 0 or 1 at last follow-up within 1 year of aSAH. RESULTS Three hundred seventy-three patients were identified with posthospital follow-up. Excellent outcome was noted in 236 patients (63.3%), including an mRS score of 0 in 122 (32.7%) and an mRS score of 1 in 114 (30.6%). On univariate analysis, the following factors were associated with an excellent outcome: indicators of less severe bleeding, such as better World Federation of Neurosurgical Societies grade at any of the times of assessment, better modified Fisher grade, and absence of intracerebral hemorrhage (ICH), intraventricular hemorrhage (IVH), and symptomatic hydrocephalus; aneurysm treatment with coil embolization; absence of symptomatic vasospasm, delayed cerebral ischemia, and radiological infarction; absence of in-hospital seizures; lack of need for CSF diversion; fewer hours with fever; less severe anemia; and absence of transfusion. On multivariable analysis, the 4 variables that were most strongly associated with excellent outcome were presence of good clinical grade after neurological resuscitation, absence of ICH on initial CT scan, blood transfusion during the hospitalization, and radiological infarctions on final brain imaging. CONCLUSIONS Excellent outcomes (mRS score 0–1) can be achieved in the majority of patients with aSAH. The likelihood of excellent outcome is predicted by good clinical condition after resuscitation, absence of ICH on presentation, no evidence of infarction on brain imaging, and absence of blood transfusion during hospitalization.